| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $199,999 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Middleton Fred A | 1 | $199,999 | 0 | $0 | $199,999 |
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor …
Over the last 12 months, insiders at CalciMedica, Inc. have bought $199,999 and sold $0 worth of CalciMedica, Inc. stock.
On average, over the past 5 years, insiders at CalciMedica, Inc. have bought $1.8M and sold $3,650 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Middleton Fred A () — $199,999.
The last purchase of 248,972 shares for transaction amount of $199,999 was made by Middleton Fred A () on 2026‑06‑25.
| 2026-06-25 | Middleton Fred A | 248,972 2.0217% | $0.80 | $199,999 | -26.52% | |||
| 2025-09-18 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,500 0.0171% | $3.07 | $7,675 | -75.20% | ||
| 2025-09-15 | Roberts Eric W | CHIEF BUSINESS OFFICER | 3,400 0.0229% | $2.68 | $9,105 | -71.37% | ||
| 2025-09-12 | Roberts Eric W | CHIEF BUSINESS OFFICER | 5,000 0.0352% | $3.12 | $15,600 | -74.20% | ||
| 2025-09-09 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,343 0.0147% | $3.15 | $7,378 | -76.82% | ||
| 2025-08-29 | Roberts Eric W | CHIEF BUSINESS OFFICER | 800 0.0058% | $2.74 | $2,192 | -68.37% | ||
| 2025-08-28 | Roberts Eric W | CHIEF BUSINESS OFFICER | 9,200 0.0691% | $2.86 | $26,340 | -68.57% | ||
| 2025-08-20 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,000 0.0142% | $2.72 | $5,440 | -67.27% | ||
| 2025-08-19 | Hebbar Sudarshan | Chief Medical Officer | 9,563 0.0694% | $2.82 | $26,962 | -67.63% | ||
| 2025-08-19 | Roberts Eric W | CHIEF BUSINESS OFFICER | 1,000 0.0072% | $2.79 | $2,790 | -67.63% | ||
| 2025-08-15 | Roberts Eric W | CHIEF BUSINESS OFFICER | 5,076 0.0362% | $2.90 | $14,709 | -68.01% | ||
| 2025-08-15 | Hebbar Sudarshan | Chief Medical Officer | 4,392 0.0302% | $2.79 | $12,267 | -68.01% | ||
| 2025-08-14 | Hebbar Sudarshan | Chief Medical Officer | 1,584 0.0112% | $2.58 | $4,095 | -64.29% | ||
| 2025-07-28 | Stauderman Kenneth A. | Chief Scientific Officer | 1,000 0.0076% | $3.96 | $3,960 | -36.12% | ||
| 2025-07-25 | Sale | Stauderman Kenneth A. | Chief Scientific Officer | 1,000 0.0069% | $3.65 | $3,650 | -33.03% | |
| 2025-07-22 | Roberts Eric W | CHIEF BUSINESS OFFICER | 1,500 0.0107% | $3.77 | $5,663 | -27.78% | ||
| 2025-07-21 | Roberts Eric W | CHIEF BUSINESS OFFICER | 1,500 0.0104% | $3.37 | $5,055 | -21.49% | ||
| 2025-07-21 | Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | 1,000 0.0081% | $3.40 | $3,400 | -21.49% | ||
| 2025-07-18 | WILSON ROBERT N | director | 4,500 0.0307% | $2.87 | $12,915 | -8.47% | ||
| 2025-07-18 | Roberts Eric W | CHIEF BUSINESS OFFICER | 2,000 0.0137% | $2.88 | $5,760 | -8.47% |
| Middleton Fred A | 1063272 33.7677% | $1.56M | 4 | 0 | <0.0001% | |
| ING GROEP NV | 1755683 55.7575% | $2.58M | 1 | 0 | ||
| HOVDE ERIC D | 10 percent owner | 1645000 52.2424% | $2.42M | 29 | 0 | |
| MELLON HBV ALTERNATIVE STRATEGIES LLC | 10 percent owner | 1003768 31.878% | $1.48M | 20 | 11 | |
| Sanderling Venture Partners VI LP | 10 percent owner | 946744 30.067% | $1.39M | 1 | 0 | <0.0001% |
| Sanderling Venture Partners VI Co Investment Fund LP | 10 percent owner | 814300 25.8608% | $1.2M | 1 | 0 | <0.0001% |
| Pacini Raymond J | CEO & President | 471675 14.9796% | $693,362.25 | 15 | 2 | |
| WILSON ROBERT N | director | 422029 13.4029% | $620,382.63 | 5 | 0 | <0.0001% |
| Roberts Eric W | CHIEF BUSINESS OFFICER | 84150 2.6725% | $123,700.50 | 25 | 0 | <0.0001% |
| Hebbar Sudarshan | Chief Medical Officer | 61539 1.9544% | $90,462.33 | 3 | 0 | <0.0001% |
| Stauderman Kenneth A. | Chief Scientific Officer | 12944 0.4111% | $19,027.68 | 2 | 1 | +20.4% |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER | 3500 0.1112% | $5,145.00 | 4 | 0 | <0.0001% |
| Bardin Stephen | Chief Financial Officer | 3000 0.0953% | $4,410.00 | 2 | 0 | +77.5% |
| Jarvis David R | 10 percent owner | 0 0% | $0 | 9 | 11 |
CalciMedica, Inc. (CALC) | $6,974,678 | 45 | -14.98% | $4.63M |
$633,070 | 27 | -5.89% | $2.04M | |
$63,749,694 | 24 | -12.24% | $6.4M | |
$117,515 | 16 | -27.38% | $1.66M | |
$287,718 | 15 | -41.45% | $5.68M |
| Increased Positions | 12 | +30.77% | 282,534 | +8.03% |
| Decreased Positions | 14 | -35.9% | 94,220 | -2.68% |
| New Positions | 7 | New | 220,647 | New |
| Sold Out Positions | 6 | Sold Out | 36,970 | Sold Out |
| Total Postitions | 37 | -5.13% | 4M | +5.35% |
| Deerfield Management Company, L.P. | $8,762.00 | 9.29% | 1.3M | 0 | 0% | 2025-09-30 |
| Soleus Capital Management, L.P. | $4,610.00 | 4.89% | 683,904 | -100,000 | -12.76% | 2025-09-30 |
| Aisling Capital Management Lp | $3,512.00 | 3.72% | 521,114 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,538.00 | 2.69% | 376,624 | +37,476 | +11.05% | 2025-09-30 |
| Geode Capital Management, Llc | $666.00 | 0.71% | 98,852 | +1,820 | +1.88% | 2025-09-30 |
| Envestnet Asset Management Inc | $517.00 | 0.55% | 76,705 | -16,728 | -17.9% | 2025-09-30 |
| Renaissance Technologies Llc | $472.00 | 0.5% | 70,000 | +34,000 | +94.44% | 2025-09-30 |
| Meritage Portfolio Management | $415.00 | 0.44% | 61,539 | +15,539 | +33.78% | 2025-09-30 |
| Stonehage Fleming Financial Services Holdings Ltd | $362.00 | 0.38% | 53,703 | +53,703 | New | 2025-09-30 |
| Sheets Smith Investment Management | $344.00 | 0.37% | 51,100 | +51,100 | New | 2025-09-30 |